Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)

NCT03446612 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped The study is terminated due to feasibility in recruitment.

Conditions

Anaemia

Interventions

DRUG: Daprodustat
DRUG: Darbepoetin alfa
DRUG: Acetylcholine
DRUG: Sodium nitroprusside
DRUG: L-N-monomethyl arginine acetate (L-NMMA)

Sponsor

GlaxoSmithKline